c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Authors:
- Io EllisIEIo Ellis
- A LockerALA Locker
- Jfr RobertsonJRJfr Robertson
- J BellJBJ Bell
- R NicholsonRNR Nicholson
- Wj GullickWGWj Gullick
- Cw ElstonCECw Elston
- Rw BlameyRBRw Blamey
Open Access
- 1 March 1991
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 63 (3) , 439-443
Abstract
Immunoreactivity for c-erbB-2 oncogene product expression has been investigated in patients with breast cancer using the polyclonal antibody 21N. Three series of patients were studied, 602 presenting with primary operable cancer, 57 with stage 3 and 123 with stage 4 disease. Representative tissue sections of each primary tumour were stained using a standard immunoperoxidase technique. Invasive tumour membrane immunoreactivity was assessed and identified in 15% of patients with primary operable cancer and 20% in the advanced breast cancer group. The results demonstrate a relationship between poorer survival and oncogene expression in all three patient groups. Patients in the primary operable cancer group with membrane oncoprotein expression had a poorer outcome, 35% 10-year survival, compared with those in which membrane expression was absent, 55% 10-year survival. The median survival of patients with stage 3 disease with c-erbB-2 membrane positivity was 17 months compared to 24 months with membrane negativity. In stage 4 disease median survival with membrane expression was 8.8 months compared to 19.7 months with no membrane expression. In addition in the series of primary cancers a correlation existed between histological grade and membrane immunoreactivity. Multivariate analysis showed histological grade to be a more powerful prognostic factor than c-erbB-2 protein expression. In conclusion, this study demonstrates, in a large series of patients presenting to one centre, that c-erbB-2 protein expression is a prognostic indicator in patients with primary operable and advanced breast disease.Keywords
This publication has 35 references indexed in Scilit:
- Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblastsCell, 1989
- Neu receptor dimerizationNature, 1989
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significanceInternational Journal of Cancer, 1989
- The significance of oncogene amplification in primary breast cancerInternational Journal of Cancer, 1989
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Cellular and molecular aspects of neoplastic progression in the mammary glandEuropean Journal of Cancer and Clinical Oncology, 1988
- OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATIONThe Lancet, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985